Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.82 |
| ▸ | CDK6 | Q00534 | 19/20 | 0.82 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.61 |
| ▸ | CCND1 | P24385 | 2/20 | 0.61 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1977560 | 0.91 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL1976564 | 0.88 | CDK4 (0.83) | CDK4CDK6CCND1FLT3 | |
| SCHEMBL1980197 | 0.85 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL1975125 | 0.84 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL1976627 | 0.84 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL12556774 | 0.82 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL6223804 | 0.81 | CDK4 (0.73) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL1978009 | 0.81 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 | |
| SCHEMBL4830895 | 0.80 | CDK4 (0.70) | CDK4CDK6CCND1 | |
| SCHEMBL12556777 | 0.80 | CDK4 (1.00) | CDK4CDK6CDK1CCNB1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980903-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8841312-B2 | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors | AMGEN INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | AMGEN INC (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350244-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | CDK4, CDKL4, CDK2 | CDK4 1/4885CDK6 4/4885CDK1 12/4885 |
| US-20110142796-A1 | Fused Pyridine, Pyrimidine and Triazine Compounds as Cell Cycle Inhibitors | CDK4, CDKL4, CDK2 | CDK4 1/4885CDK6 4/4885CDK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.